Neurogene (Neurogene) Treasury Stock : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Neurogene Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Neurogene's treasury stock for the quarter that ended in Mar. 2024 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Neurogene Treasury Stock Historical Data

The historical data trend for Neurogene's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurogene Treasury Stock Chart

Neurogene Annual Data

Trend

Dec21

Dec22

Dec23

Treasury Stock

Neurogene Quarterly Data
	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Treasury Stock	Get a 7-Day Free Trial			-	-	-	-	-

Neurogene Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Neurogene (Neurogene) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

535 W 24th Street, 5th Floor, New York, NY, USA, 10011

Website

https://www.neurogene.com

Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.

Neurogene (Neurogene) Headlines

From GuruFocus

Neurogene Announces Business Update and 2024 Outlook

By Business Wire • 01-05-2024

Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million

By Business Wire • 12-19-2023